Abdul Siddiqui, MD
Infectious Disease · Auburn, WANPI 1073552709
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $766 of the $1,200 with a category attached, or 63.8%. 11 manufacturers reported payments, led by Astellas Pharma US Inc at 27.7% of the total.
Across 40 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$333
- AbbVie$192
- Insmed, Inc.$184
- Aimmune Therapeutics, Inc.$106
- Merck$100
- Janssen Products, LP$85
- plus $200 from 5 others
What the payments were for
- Food & beverage$76664%
- Education$43436%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $333 |
| AbbVie(2 entities) | 6 | $192 |
| Insmed, Inc. | 9 | $184 |
| Aimmune Therapeutics, Inc. | 4 | $106 |
| Merck | 5 | $100 |
| Janssen Products, LP | 1 | $85 |
| Gilead | 3 | $66 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| Viiv Healthcare Company | 2 | $43 |
| GSK | 1 | $22 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
How this compares
$1,200 in reported general payments places this provider in the 80th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 20 | $21,948 |
| ErtapenemErtapenem Sodium | 15 | $4,635 |
| Vancomycin Hcl | 15 | $2,309 |
| Doxycycline Monohydrate | 30 | $1,916 |
| Cephalexin | 32 | $1,080 |
| NitrofurantoinNitrofurantoin Macrocrystal | 27 | $753 |
| Amoxicillin | 19 | $565 |
| Cefazolin Sodium | 15 | $527 |
| Cefadroxil | 23 | $409 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $357 |
| Mupirocin | 13 | $183 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Auburn
- Arnold Paul CuaAuburn$407
- Francis RiedoKirkland$183K
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Anna WaldSeattle$103K
- Jim BoonyaratanakornkitSeattle$62K
- Michael BoeckhSeattle$59K
- Jason GoldmanSeattle$58K
- Connie CelumSeattle$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.